Roche May Be Riding A Bit Too High, But Remains Interesting

Core Insights - Roche experienced a 19% stock rally in November, driven by investor enthusiasm for its drug programs, including Gazyva for lupus, fenebrutinib for multiple sclerosis, and giredestrant for breast cancer [1] Company Performance - The positive market reaction helped mitigate the impact of a disappointing third-quarter performance [1]